AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8015504
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (dl-norgestrel and estradiol-17 beta) for six cycles
Trial: 8015504
Drug: dl-norgestrel alone
RxNorm normalized name: Norgestrel
DrugBank: Norgestrel (DB09389)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dl-norgestrel alone (0.075 mg/day) for two cycles
Trial: 2597712
Drug: Behavioral Stepped-Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Stepped-Care treatment program (systolic feedback)
Trial: 2597712
Drug: Behavioral Stepped-Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Stepped-Care treatment program (relaxation)
Trial: 53554
Drug: Cimetidine 1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 1.6 g/day
Trial: 29345724
Drug: Cognitive training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive training (12-week program, twice a week for 45 minutes)
Trial: 27698953
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (1.14 g/day)
Trial: 17140647
Drug: Fluticasone monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone monotherapy
Trial: 17140647
Drug: PACT combination
RxNorm normalized name: Poly Pact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PACT combination
Trial: 14557438
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol (1 mg every 12 h)
Trial: 14557438
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (200 micro g/d)
Trial: 14557438
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (50 micro g/d)
Trial: 8984849
Drug: Risperidone (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (various doses)
Trial: 1311964
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg oral dose of dl-fenfluramine
Trial: 2992724
Drug: Five-drug combination
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-drug combination (vincristine, doxorubicin, cisplatin, etoposide, cyclophosphamide)
Trial: 25588320
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam microdose (0.001 mg)
Trial: 25588320
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam regular dose (1 mg)
Trial: 25588320
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam microdose (0.003 mg)
Trial: 25588320
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam regular dose (3 mg)
Trial: 23551803
Drug: Calcitonin nasal
RxNorm normalized name: calcitonin nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin nasal spray 200 IU
Trial: 23551803
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline (placebo) spray
Trial: 19738321
Drug: L-DOPA 100
RxNorm normalized name: L-DOPA 100 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-DOPA 100 mg daily for 5 weeks
Trial: 11230723
Drug: EPO treatment
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPO treatment for ICU anemia
Trial: 9204224
Drug: Self-administered food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered food frequency questionnaire (FFQ)
Trial: 8271800
Drug: Behavioral marital
RxNorm normalized name: barbital
DrugBank: Barbital (DB01483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral marital therapy (BMT) alone
Trial: 10718774
Drug: Solution
RxNorm normalized name: Solution
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solution
Trial: 21275549
Drug: Alendronate (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (35 mg/week)
Trial: 21275549
Drug: Control (Vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Vitamin D, alfacalcidol 1 μg/day)
Trial: 19074924
Drug: Changes in
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changes in QRS duration over 60 min after fibrinolytic therapy
Trial: 17276969
Drug: Sibutramine 10
RxNorm normalized name: sibutramine 10 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 10 mg daily for 12 weeks
Trial: 14975462
Drug: Reduced-dose tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-dose tenecteplase (0.27 microg/kg) plus high-dose eptifibatide (2 boluses of 180 microg/kg separated by 10 min, 2.0 microg/kg/min infusion)
Trial: 14975462
Drug: Reduced-dose tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-dose tenecteplase plus high-dose eptifibatide
Trial: 11532409
Drug: SPI experience
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TOPICAL GEL [Quality Metalcraft Experi-Metal Alcohol Antiseptic 80% Topical Solution Hand Sanitizer Non-sterile Solution]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPI experience discussing rectal cancer
Trial: 9541083
Drug: Operant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operant treatment alone
Trial: 9541083
Drug: Common individual
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common individual rehabilitation therapy
Trial: 2853934
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate 50 mg three times daily
Trial: 2853934
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate 100 mg three times daily
Trial: 2853934
Drug: Depot GnRH
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Depot GnRH agonist alone
Trial: 25458542
Drug: PiMg (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PiMg (sodium picosulfate and magnesium citrate 500 mL plus 2L of clear fluids)
Trial: 16396766
Drug: Topotecan 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan 1.25 mg/m² on days 1-5 for three 21-day cycles, followed by thalidomide starting at 100 mg/day (escalated to 300 mg/day if tolerated) for up to 1 year.
Trial: 16396766
Drug: Thalidomide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (100 mg/day, escalated to 300 mg/day if tolerated) for up to 1 year.
Trial: 12755459
Drug: Day treatment
RxNorm normalized name: Pharmacist Clotrimazole 3 Day Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day treatment plus contingency management (DT+)
Trial: 12755459
Drug: Day treatment
RxNorm normalized name: Pharmacist Clotrimazole 3 Day Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day treatment (DT)
Trial: 31765805
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of QLV and RV-LV
Trial: 21679268
Drug: Quality of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality of life (QOL) assessment among treatment seeking MA users
Trial: 19365295
Drug: Prescription copayment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription copayment (copay) policy
Trial: 17020440
Drug: Overall frequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall frequency of hospitalisation, emergency treatment, use of medication, detoxification
Trial: 15496647
Drug: Oxcarbazepine 5
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine 5 mg/kg
Trial: 15496647
Drug: Oxcarbazepine 15
RxNorm normalized name: oxcarbazepine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine 15 mg/kg
Trial: 15496647
Drug: Oxcarbazepine doses
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine doses of 11 to 68 mg/kg/day
Trial: 24330605
Drug: RP-G28 (galacto-oligosaccharide)
RxNorm normalized name: RP-72
DrugBank: RP-72 (DB17156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RP-G28 (galacto-oligosaccharide) administered for 35 days
Trial: 20542888
Drug: Intraoperative high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative high-dose remifentanil (0.25 microg kg(‐1) min(‐1))
Trial: 20542888
Drug: Intraoperative low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraoperative low-dose remifentanil (0.1 microg kg(‐1) min(‐1))
Trial: 23860366
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) therapy at 67 µg/kg/day for 1 year
Trial: 21170205
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Withania somnifera and Terminalia arjuna (500mg/day each)
Trial: 21170205
Drug: Placebo (capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (capsules filled with flour)
Trial: 17684475
Drug: NRTIs (nucleoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRTIs (nucleoside reverse transcriptase inhibitors)
Trial: 16648247
Drug: Low-dose melatonin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose melatonin administration in the morning
Trial: 16648247
Drug: Low-dose melatonin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose melatonin administration in the afternoon/evening
Trial: 16648247
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light exposure (treatment of choice)
Trial: 11128877
Drug: Toluene exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toluene exposure (measured by urinary excretion of unmodified toluene)
Trial: 11128877
Drug: Cumulative toluene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative toluene exposure (estimated as product of urinary excretion and previous exposure duration)
Trial: 8799521
Drug: Diltiazem (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (180 mg day‐1 for 1 week)
Trial: 1395875
Drug: Surgery plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery plus preoperative chemotherapy
Trial: 31612147
Drug: Propolis spray
RxNorm normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propolis spray (3%) applied to cover the entire wound surface during dressing changes from week 0 until cicatrization or a maximum of 8 weeks.
Trial: 31612147
Drug: Propolis spray
RxNorm normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propolis spray (3%)
Trial: 29443664
Drug: Nusinersen (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nusinersen (12 mg, intrathecal administration on days 1, 29, 85, and 274)
Trial: 27908454
Drug: Fulvestrant 500
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant 500 mg intramuscular injection (days 0, 14, 28, then every 28 days thereafter)
Trial: 27908454
Drug: Anastrozole 1
RxNorm normalized name: anastrozole 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole 1 mg orally daily
Trial: 22422103
Drug: Immuno-chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immuno-chemotherapy
Trial: 15772570
Drug: CEE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.625 mg/d combined with MPA 2.5 mg/d (n = 20)
Trial: 15772570
Drug: CEE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.625 mg/d combined with MPA 5 mg/d (n = 20)
Trial: 15772570
Drug: Unopposed CEE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unopposed CEE 0.625 mg/d (n = 20)
Trial: 10406359
Drug: Vigabatrin 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin 2 g daily
Trial: 10406359
Drug: Carbamazepine 600
RxNorm normalized name: carbamazepine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine 600 mg daily
Trial: 7776521
Drug: Intravenous injections
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injections of fentanyl 10‐13 micrograms.kg‐1 during lower abdominal surgery under light general anesthesia (halothane 0.3‐0.5% plus nitrous oxide and oxygen)
Trial: 7776521
Drug: Lumbar epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar epidural anesthesia (intermittent injections of 1.0% lidocaine) during lower abdominal surgery under light general anesthesia
Trial: 7776521
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural anesthesia (intermittent injections of 1.0% lidocaine) during upper abdominal surgery under light general anesthesia
Trial: 2222129
Drug: Abrupt discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abrupt discontinuation of short half-life benzodiazepines
Trial: 2222129
Drug: Abrupt discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abrupt discontinuation of long half-life benzodiazepines
Trial: 8740611
Drug: Active drugs
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drugs
Trial: 26605240
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus atypical antipsychotic
Trial: 18752540
Drug: IntraSite Gel
RxNorm normalized name: Intrasite Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IntraSite Gel (hydrogel)
Trial: 11069572
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) - beclomethasone dipropionate 200 microg or budesonide 200 microg, prescribed twice daily
Trial: 11069572
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group - beta2-agonist only
Trial: 9235813
Drug: Piroxicam-beta-cyclodextrin 20
RxNorm normalized name: piroxicam-beta-cyclodextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam-beta-cyclodextrin 20 mg daily for 14 days
Trial: 9235813
Drug: Piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 20 mg daily for 14 days
Trial: 1441691
Drug: slow-release gallopamil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: slow-release gallopamil, 100 mg b.i.d.
Trial: 1441691
Drug: slow-release nifedipine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: slow-release nifedipine, 20 mg b.i.d.
Trial: 29570019
Drug: CP (37%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP (37% carbamide peroxide gel)
Trial: 29570019
Drug: HP (35%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP (35% H2O2 gel)
Trial: 29570019
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no bleaching agent)
Trial: 11858475
Drug: Low-molecular-weight heparin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin, dalteparin (N = 21) once daily subcutaneously
Trial: 11858475
Drug: Unfractionated sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfractionated sodium heparin (UF heparin, N = 23) twice daily subcutaneously
Trial: 10074877
Drug: Clozapine (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine (maximum dose of 300 mg/day)
Trial: 10074877
Drug: Chlorpromazine (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (maximum dose of 600 mg/day)
Trial: 2024753
Drug: Lignocaine 1.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 1.5% with 1/200,000 adrenaline (group L)
Trial: 7215756
Drug: Calcium heparin
RxNorm normalized name: HEPARIN CALCIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium heparin (7,500 i.u. subcutaneous twice daily)
Trial: 7215756
Drug: Semi-synthetic heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semi-synthetic heparin analogue (5,000 U subcutaneous twice daily)
Trial: 30591535
Drug: Low-dose CT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT (LDCT) lung cancer screening
Trial: 19775999
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy after breast-conserving surgery (BCS)
Trial: 19775999
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy after complete mastectomy
Trial: 19775999
Drug: Breast conservative
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast conservative surgery without radiation therapy
Trial: 7793647
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine (150 mg)
Trial: 7793647
Drug: 0.5% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% ropivacaine (150 mg)
Trial: 1903598
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone infusion (45 ng.kg‐1.min‐1)
Trial: 7017100
Drug: Droperidol (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol (0.05 mg/kg, intravenously administered)
Trial: 23373664
Drug: Partial directly
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial directly observed antiretroviral therapy (DOT‐ART)
Trial: 23373664
Drug: Self‐administered ART
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self‐administered ART (Self‐ART)
Trial: 20031735
Drug: Intracoronary adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary adenosine (2 x 120 microg in 20 mL NaCl)
Trial: 20031735
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 x 20 mL NaCl)
Trial: 17352768
Drug: IL-2 (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-2 (7.5 MIU twice a day, for 5 days every 8 weeks)
Trial: 12365878
Drug: ethyl-eicosapentaenoate 1
RxNorm normalized name: Ethyl eicosapentaenoate
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ethyl-eicosapentaenoate 1 g/d
Trial: 12365878
Drug: ethyl-eicosapentaenoate 2
RxNorm normalized name: Ethyl eicosapentaenoate
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ethyl-eicosapentaenoate 2 g/d
Trial: 12365878
Drug: ethyl-eicosapentaenoate 4
RxNorm normalized name: Ethyl eicosapentaenoate
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ethyl-eicosapentaenoate 4 g/d
Trial: 9521435
Drug: Beta-carotene and
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene and vitamin A supplementation (30 mg of beta-carotene and 25,000 IU of retinyl palmitate)
Trial: 7855556
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tobramycin and cefuroxime (T/C)
Trial: 2535678
Drug: usual anti-hypertensive
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: usual anti-hypertensive therapy
Trial: 31917100
Drug: 3 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg/day of ferrous sulfate
Trial: 21711174
Drug: Soy (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy (2 mg/kg body weight aglycone equivalent isoflavones)
Trial: 21711174
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of seaweed (5 g/day) and soy
Trial: 18064563
Drug: Fluoxetine (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (daily oral for 6 months)
Trial: 26009003
Drug: High-intensity games
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity games intervention (twice-weekly, 40 min sessions for 6 weeks)